Dublin, May 26, 2021 (GLOBE NEWSWIRE) -- The "Drug-Eluting Stents Market by Coating, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
The global drug-eluting stents market was valued at $6,382 million in 2019, and is projected to reach $8,777 million by 2027, registering a CAGR of 8.7% from 2020 to 2027.
Drug-eluting stents (DES) are small cylindrical stents that aid in improving blood flow through arteries to heart by minimizing blockages. They are usually used in the treatment of percutaneous coronary intervention or coronary angioplasty. There are two types of DES available, namely, polymer-based coating DES and polymer free coating DES. Polymer-based drug-eluting coating stents are designed to allow consistent and controlled release of drug from stent surface into arteries. They are used in coronary artery disease and peripheral artery disease.
Increase in prevalence of diabetes, obesity, and high blood pressure worldwide have led to rise in incidences of cardiovascular diseases (CVD), coronary heart disease, and heart failure. This, in turn, is expected to boost growth of the drug-eluting stents market during the forecast period. In addition, surge in number of product approvals, rise in popularity of polymer technology for production of stents, and surge in reimbursement policies supported by governments are the key factors that fuel growth of the global drug-eluting stents market. Moreover, rise in geriatric population propels growth of the market as geriatric population is at high risk of developing arterial disorders. However, product recall and risks associated with DES restricts growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period.
The global drug-eluting stents market is segmented on the basis of coating, application, end user, and region. On the basis of coating, the market is divided into polymer-based coating and polymer free coating. The polymer-based coating segment is further bifurcated into biodegradable and non-biodegradable. The polymer free coating segment is further divided into microporous surface, microstructured surface, slotted tubular surface, and nanoporous surface. By application, the market is categorized into coronary artery disease and peripheral artery disease. By end user, the market is bifurcated into hospitals, ambulatory surgical centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of four regions is provided to determine the existing opportunities.
- Profiles and growth strategies of key players are thoroughly analyzed to understand the competitive outlook of the global market.
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter's five force analysis
3.4. Top player positioning, 2019
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in prevalence of cardiovascular disease
3.5.1.2. Surge in demand for minimally invasive surgical procedures
3.5.1.3. Introduction of advanced drug eluting stents
3.5.2. Restraint
3.5.2.1. Stringent government regulations
3.5.3. Opportunities
3.5.3.1. Growth opportunities in emerging markets
3.5.4. Impact analysis
3.6. Covid-19 Impact analysis on drug-eluting stents market
CHAPTER 4: DRUG-ELUTING STENTS MARKET, BY COATING
CHAPTER 5: DRUG-ELUTING STENTS MARKET, BY APPLICATION
CHAPTER 6: DRUG-ELUTING STENTS MARKET, BY END USER
CHAPTER 7: DRUG-ELUTING STENTS MARKET, BY REGION
CHAPTER 8: COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. ALVIMEDICA
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Key strategic moves and developments
8.3. B. BRAUN HOLDING GMBH & CO. KG
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. BIOSENSORS INTERNATIONAL GROUP, LTD
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Key strategic moves and developments
8.5. BIOTRONIK, INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Key strategic moves and developments
8.6. BOSTON SCIENTIFIC CORPORATION
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. COOK GROUP (COOK MEDICAL)
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Key strategic moves and developments
8.8. MEDTRONIC PLC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. STENTYS SA
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. TERUMO CORPORATION
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
For more information about this report visit https://www.researchandmarkets.com/r/7cauc1